Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2015 06:00 ET | Source: MediciNova, Inc.

MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

LA JOLLA, Calif., June 12, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
June 03, 2015 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease

LA JOLLA, Calif., June 3, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
May 07, 2015 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

LA JOLLA, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code...
April 23, 2015 19:00 ET | Source: MediciNova, Inc.

Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Presented at the American Academy of Neurology (AAN) 67th Annual Meeting

LA JOLLA, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 21, 2015 13:45 ET | Source: MediciNova, Inc.

MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS

LA JOLLA, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 16, 2015 08:30 ET | Source: MediciNova, Inc.

Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan

LA JOLLA, Calif., April 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 16, 2015 08:00 ET | Source: MediciNova, Inc.

FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis

LA JOLLA, Calif., April 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
March 02, 2015 18:00 ET | Source: MediciNova, Inc.

MN-166 (Ibudilast) Effects in Opioid Dependence Selected for Presentation at the 77th Annual Meeting of the College on Problems of Drug Dependence in Phoenix, Arizona

LA JOLLA, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 25, 2015 18:00 ET | Source: MediciNova, Inc.

MediciNova's MN-001 (tipelukast) NASH with Advanced Fibrosis Abstract Accepted for Presentation at the AASLD and Industry Colloquium: Novel Targets and Therapies in Liver Disease in Durham, North Carolina

LA JOLLA, Calif., Feb. 25, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
February 16, 2015 18:00 ET | Source: MediciNova, Inc.

MediciNova Provides Update on Clinical Trial of MN-166 (Ibudilast) in ALS

LA JOLLA, Calif., Feb. 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...